Pinc PeptideThe girly peptide research blog

Repair & recovery · Evidence tier B · #4 in test requests

BPC-157

BPC 157 · Body Protection Compound-157 · Body Protective Compound-157 · Bepecin · PL-14736 (PL 14736) · PLD-116

BPC-157 is a lab-made peptide sold for tendon, joint and gut healing. It is not approved anywhere, and the only placebo-controlled trial in patients that FDA found showed no clear benefit1.

Last reviewed · First published · 56 sources · 34 min read · By the Pinc Peptide editors

Illustration: a glass vial with a pink label reading BPC-157
Illustration, not a real product: an empty glass vial (photo: Missouri Historical Society, public domain) with our label. See every vial.

Quick answers

What is it?
A lab-made chain of 15 amino acids, sold online for tendon, joint and gut healing. It is not approved as a medicine anywhere1.
Does it work?
Not shown in people. The only placebo-controlled trial in patients that FDA found, for a bowel disease, showed no clear benefit1. Three other small reports had no comparison group345. Claims about healing injuries come from animal studies16.
Is it safe?
Unknown. The studies FDA found gave it to fewer than 100 people, for 2 weeks or less; an 8-week gummy study has posted no results119. In rats and dogs, FDA saw possible signs of altered clotting and raised liver markers140. Its cancer risk is untested1.
Is it legal?
Not approved, and US pharmacies may not make it12. In July 2026, FDA’s advisers voted 8-6 to recommend letting pharmacies make it7. FDA had not changed the rules by 30 September 202628. Banned in sport1112.
What is in the vials?
Many tested samples fail: Finnrick, a testing service, failed 92 of its latest 200 (May to September 2026), though people choose which samples to send946. A vial from a Brooklyn corner shop, tested for WIRED in August 2026, held no BPC-15710.

What it is

BPC-157 is a synthetic peptide, a chain of 15 amino acids. BPC stands for ‘body protection compound’6. FDA describes it as a fragment of the BPC protein originally isolated from human gastric juice113. How it works is not known: FDA says its molecular targets have not been identified and its mechanisms of action ‘remain poorly understood’1. Animal and cell studies suggest it may promote the growth of new blood vessels (angiogenesis), raise levels of growth factor receptors such as VEGFR2, dampen inflammatory signals and stimulate nitric oxide production114. Products sold as BPC-157 include injection kits, capsules, and oral and nasal sprays1.

Researchers at the University of Zagreb, Croatia, first synthesized BPC-157 in the early 1990s, and Sikirić and colleagues described it in 1993113. By 2003 it was reported to be in clinical trials for inflammatory bowel disease under the codes PL 14736 and PLD-116 (Pliva)15. Enema studies in healthy volunteers and in people with ulcerative colitis were reported in 2002, 2003 and 2005; FDA found only meeting abstracts of them, and no product was approved1. In 2015 the company PharmaCotherapia registered a study of oral ‘Bepecin’ tablets in healthy volunteers in Tijuana, Mexico; it has posted no results, and FDA found no published study from it116.

Benefits: what the research shows

The best human evidence is one small controlled trial, and it did not show a benefit. In a Phase II trial that FDA found reported only in a 2005 meeting abstract, 53 people with mild to moderate ulcerative colitis were randomized to an 80 mg BPC-157 enema or a placebo enema once daily for 2 weeks, and 46 finished1. A disease activity score fell 3.2 points on BPC-157 and 1.6 points on placebo, but the 95% confidence interval for the difference between groups (-4.84 to 1.62) included zero, so the difference was not statistically significant1. The authors reported no difference in side effects versus placebo, but FDA called the data inadequate to support efficacy or safety1. An earlier placebo-controlled enema study in 32 healthy male volunteers (24 given BPC-157) found no significant adverse events attributable to the drug; headache and flatulence were the most frequent complaints, with no obvious difference from placebo1. The other published reports have no control group and share one first author at private clinics in Florida: 14 of 16 knee-pain patients reached by phone said knee injections of BPC-157 (alone or with thymosin beta-4) relieved their pain3, 10 of 12 women with interstitial cystitis (bladder pain syndrome) reported complete relief after injections into the bladder wall4, and 2 people reported no side effects from IV infusions of up to 20 mg5. None of the five clinical studies FDA found gave BPC-157 by injection under the skin (subcutaneous), by mouth or in the nose1. Claims for tendon, ligament, muscle and bone healing rest on animal work. A 2025 systematic review found 36 relevant studies, 35 of them preclinical, and ‘no clinical safety data’6. In rats, BPC-157 sped the healing of cut Achilles tendons15. But in a 2026 rat Achilles study with 8 animals per group, only TB-500 significantly improved tendon strength; BPC-157’s gains on total tissue scores were not statistically significant, and combining the two added no benefit over either alone18. Registered human studies have not filled the gap: a 2015 oral tablet study has posted no results16, an industry study of BPC-157 gummies (500 µg per serving) finished in November 2025 but has posted no results either19, and a rotator cuff surgery trial is not due to start until January 202720. A 2026 hamstring ‘trial’ listing (NCT07437547) is not counted here, because another record from the same sponsor calls itself ‘fictional’2122. We grade the evidence tier B because at least one completed controlled human trial has public results, but it is a weak B: FDA found one controlled trial in patients, which was small and negative and reported only in a meeting abstract1.

Key human studies

StudyDesignPeopleDose and routeResult
Ruenzi M, Stolte M, Veljaca M, Oreskovic K, Peterson J, UCS Group. A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study of PL 14736 Enema in the Treatment of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2005;128:A584 (meeting abstract, as summarized by FDA in 2026)1Source Multicenter, randomized (1:1), double-blind, placebo-controlled Phase II trial in mild to moderate ulcerative colitis; meeting abstract only 53 80 mg rectal enema or placebo once daily for 2 weeks 46 of 53 completed. The disease activity score fell 3.2 points (95% CI -5.58 to -0.82) on BPC-157 vs 1.6 points (95% CI -3.86 to 0.67) on placebo; the 95% CI for the difference between groups (-4.84 to 1.62) included zero. Withdrawals for adverse events were 3 vs 2, ‘mainly progression of UC’ (ulcerative colitis). FDA called the data inadequate to support efficacy or safety1.
Veljaca M et al. The Development of PL 14736 for Treatment of Inflammatory Bowel Disease. IUPHAR-GI Section Symposium, Honolulu, 2002 (abstract O-32); Veljaca M et al. Safety, Tolerability and Pharmacokinetics of PL 14736, a Novel Agent for Treatment of Ulcerative Colitis, in Healthy Male Volunteers. Gut 2003;51:A309 (meeting abstracts, as summarized by FDA in 2026)1Source Placebo-controlled Phase 1 tolerability and pharmacokinetic study in healthy male volunteers; meeting abstracts only 32 Rectal enema of 0.25, 0.5, 1 or 2 mg/kg (6 on BPC-157 and 2 on placebo per dose group): one dose, a 1-week washout, then once daily for 7 days No significant adverse events attributable to single or repeated 7-day treatment. Headache and flatulence were the most frequent adverse events, with no obvious difference in frequency or severity from placebo. Most plasma levels were below the assay’s lower limit of quantification1.
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-133PubMed Retrospective chart review (2019 to 2020) at one Florida clinic with telephone follow-up; no control group and no standard outcome measures 17 Knee (intra-articular) injection of BPC-157 alone (12 of the 16 reached by phone) or with thymosin beta-4 (4); 2 to 4 mg of BPC-157, 1 or 2 doses (per FDA) 16 of the 17 patients were reached by phone, most of them 6 months to 1 year after the injection. 11 of 12 on BPC-157 alone and 3 of 4 on the combination reported significant pain relief (14 of 16 overall)3. The authors noted no adverse events1.
Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-174PubMed Single-arm pilot study at a private Florida clinic in women with moderate to severe interstitial cystitis who had not responded to pentosan polysulfate; no control group 12 One cystoscopy procedure: compounded BPC-157 (from a 503A pharmacy), 1 mg injected at each of 10 sites in the bladder wall (10 mg total) 10 of 12 reported complete resolution of symptoms and rated their success at 100%; the other 2 rated it at 80%. All 12 scored 5 of 5 on the Global Response Assessment. No dropouts and no adverse events were reported4.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-245PubMed Uncontrolled, IRB-approved safety pilot at a private Florida clinic; both participants had used IV BPC-157 before 2 IV infusion over 1 hour: 10 mg on day 1, then 20 mg on day 2 No side effects were reported, and there were no measurable effects on blood markers of heart, liver, kidney or thyroid function or on blood glucose5.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

None of the five clinical studies FDA found tested injection under the skin, oral use or nasal use1. Doses in published studies: a rectal enema of 0.25, 0.5, 1 or 2 mg/kg, once and then daily for 7 days, in healthy volunteers1; an 80 mg enema daily for 2 weeks in ulcerative colitis, with no significant benefit1; 2 to 4 mg injected into the knee, 1 or 2 times13; 10 mg injected into the bladder wall in one procedure4; and 10 mg by IV infusion on day 1, then 20 mg on day 25. A 2015 oral study planned single doses of 1, 3 or 6 mg, then 3 mg every 8 hours for 2 weeks; it has posted no results, and FDA found no published study from it116. An industry study in which 40 people took two BPC-157 gummies a day for 8 weeks (500 µg per serving) finished in November 2025 but has posted no results19.

In animal studies

Early animal studies mostly used very low doses, in the microgram and nanogram per kg range13. Rat healing studies typically gave 10 µg/kg or 10 ng/kg once daily, injected into the abdominal cavity (intraperitoneal) or added to drinking water115. The 2003 Achilles tendon study also tested 10 pg/kg15, and a 2026 Achilles study used 10 µg/kg per day for 4 weeks18. FDA notes that dose-response relationships for its effects on gut and liver injuries have not been established1. Toxicology studies used far larger intramuscular doses: the highest single doses with no observed adverse effects were 20 mg/kg in rats and 10 mg/kg in dogs, and 28-day studies went up to 4 mg/kg per day in rats and 2 mg/kg per day in dogs140. These are animal research doses, not human doses.

What users report Anecdotal · not validated · not a recommendation

One community reference page lists 500 µg (micrograms) per dose, once or twice a day41.

Half-life
About 15 minutes in rats and 5 minutes in dogs after an IV dose; unknown in humans39Animal data only: after single IV doses, 15.2 minutes in rats (20 µg/kg) and 5.3 minutes in dogs (6 µg/kg)1. The study authors report a half-life under 30 minutes and rapid breakdown into small peptide fragments39. FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use; in the enema studies, BPC-157 was not detected in most plasma samples1.
Routes
  • Subcutaneous injection (not used in any clinical study FDA found)
  • Oral capsules, tablets, gummies and sprays (sold as supplements and compounded products; a 2015 oral study and a 2025 gummy study have posted no results)
  • Nasal spray (no human data found)
  • Intramuscular injection (animal studies only)
  • Rectal enema (human studies reported 2002 to 2005)
  • Knee (intra-articular) injection (retrospective case series)
  • Injection into the bladder wall (single-arm pilot)
  • Intravenous infusion (2-person pilot)
  • Transdermal cream (proposed in a withdrawn compounding nomination; no human data found)

Every dose studied for BPC-157, with sources →

Quality and the gray market

What testing finds

Independent tests often find problems. Finnrick, an independent peptide-testing company in Austin, Texas10, had published 900 BPC-157 tests covering 144 vendors between 17 December 2024 and 25 September 2026. Of its latest 200 tests (27 May 2026 to 25 September 2026), 106 passed, 92 failed and 2 were incomplete, a 46.5% failure rate among completed tests9. Under the ‘purity focus’ standard shown on that page, a sample fails if it has the wrong identity, purity below 99.5% or an amount more than 35% off the label claim42. The best-rated vendor on the page scored 75%9. Finnrick obtains samples from vendors and sends them to outside labs, and it also offers free testing of samples mailed in by US users, so its results describe the products it tested, not a random sample of the market942. A BPC-157 vial bought at a Brooklyn bodega and tested for WIRED (results in August 2026) contained no BPC-157; heavy metals and endotoxins were low10. FDA says it has encountered multiple salts and derivatives, including different active molecules, sold under the same name1. In Canada, BPC-157 powder supplied to pharmacies was recalled in May 202629.

How it is sold

BPC-157 is sold online as RUO powder in vials, and as capsules, oral and nasal sprays and injection kits through compounders, clinics and telehealth services1. One seller’s page says its products are ‘strictly for research use only (RUO)’ and not approved for human use43, but Health Canada and the UK’s MHRA say such labels do not put products outside drug law2832. FDA quotes a clinic website saying BPC-157 has been called the ‘wolverine compound’1, and it is often combined with TB-500 in a pairing called the ‘Wolverine stack’44. One vendor page listed a single 20 mg vial with 10 mg of each peptide at $90, marked down from $149.99, on 1 October 202643. A Health Canada alert of 24 December 2025 listed seized blends sold as ‘Glow’ (BPC-157, TB-500 and GHK-Cu) and ‘Klow’ (the same plus KPV)45, and FDA found nasal sprays that combine BPC-157 with a thymosin beta-4 fragment1. Some pharmacies and clinics also sell an arginine salt of BPC-157, described in a 2017 US patent, as pentadeca arginate, or PDA; we found no published study of it in people53545556. Demand is rising. An nference analysis of more than 15 million medical files (a preprint, not peer reviewed) found 1,039 patients whose doctors had recorded BPC-157 use, with new users up 33-fold from 2020 to 202644. BPC-157 was the fourth most requested product in Finnrick’s test-request data from May 2025 to May 2026 (1,376 of 21,253 requests, 6.5%)46. The r/BPC_157 subreddit had 19,037 weekly visitors on 30 September 202647. Rising US Google searches for ‘bpc 157’ in the 12 months to 29 September 2026 included ‘bpc 157 pharmacy compounding vote’, ‘wolverine stack’ and ‘klow peptide’48.

Side effects and risks

  • Unknown human safety: the five published clinical studies FDA found gave BPC-157 to fewer than 100 people, for 2 weeks or less. FDA says they were small and short, used likely exploratory doses, gave limited safety information, and that safety monitoring in most of them was unclear1. An 8-week study of BPC-157 gummies in 40 people finished in 2025 but has posted no results19.
  • Immune reactions: FDA says that, as a 15-amino-acid peptide given by injection or nasal spray, BPC-157 ‘may pose a significant risk for immunogenicity’ (triggering unwanted immune responses), possibly made worse by clumping (aggregation) and impurities; FDA found no study that tested this126.
  • Animal toxicology signals: FDA says 28-day studies in rats and dogs ‘appeared to be associated with clinically relevant safety signals’, including altered blood clotting times and raised liver-related blood markers (ALT, glucose and triglycerides), although the study authors called BPC-157 well tolerated140.
  • Cancer risk is untested: there are no carcinogenicity studies1. BPC-157 promotes blood vessel growth in animal and cell studies14; a 2026 review lists pathological blood vessel growth and cancer among the potential risks of unapproved peptides such as BPC-15749, and Health Canada lists the growth of cancerous tumors among the risks of unauthorized injectable peptides28.
  • Wrong or missing contents: 92 of Finnrick’s latest 200 tests failed its purity-focused standard (at least 99.5% pure and within 35% of the labeled amount), a bodega vial contained no BPC-157, FDA has seen different salts and derivatives sold under one name, and Health Canada warns that unauthorized peptides may contain too much, too little or none of the active ingredient19102842.
  • Blends make reactions hard to trace: after a skin-darkening reaction that recurred on re-use of a BPC-157 and TB-500 product, FDA could not tell which peptide was responsible1.
  • Legal and anti-doping risk: FDA has issued a warning letter covering BPC-157 sales, a Utah physician was indicted over BPC-157 and other peptides, possession without authority is illegal in Australia, and athletes have received 4-year bans23243136.

Documented harms

  • 11 May 2026FDA’s review describes a report to FAERS (the FDA Adverse Event Reporting System) from a 40-year-old woman who injected a ‘research purposes only’ BPC-157 and TB-500 product under the skin for ‘joint healing and wound healing support’. After one week she developed diffuse skin darkening (hyperpigmentation) and darkened gums; the same reaction recurred when she used the product again two weeks later, and she had no further reactions after stopping. FDA judged the product the likely cause but could not assess BPC-157’s role because the product contained two peptides1.
  • 11 May 2026Two other FAERS reports involved compounded BPC-157 injections: 9 days of redness and swelling around the injection site in a 55-year-old woman who was also injecting compounded thymosin, and shortness of breath leading to an emergency room visit in a 28-year-old man. FDA said the other injections in the first case, and missing details in the second, limit interpretation1.
  • 11 May 2026FDA’s Human Foods Complaint System (HFCS), which collects reports on foods, dietary supplements and cosmetics, held 3 BPC-157 cases through 3 December 2025. All were complicated by multi-ingredient supplements, other medicines or missing details1.
  • 16 Sep 2026Reuters reported that data from FDA’s Adverse Event Monitoring System (formerly FAERS) show 10 reports of serious adverse events involving BPC-157 since 2021, 8 of them in 2026. FDA notes that a report does not confirm the product caused the event44.
  • 16 Sep 2026In nference’s analysis of health records for 1,039 BPC-157 users (a preprint, not peer reviewed), outcomes were recorded for only one-third, and some patients reported gastrointestinal, skin or neuropsychiatric side effects44.

Questions people ask

Is BPC-157 FDA approved?

No. FDA has not approved BPC-157 for any use, and its 2026 review found no approved BPC-157 product in any country1. On 23 July 2026 PCAC, an FDA advisory committee, voted 8-6 with 1 abstention to recommend allowing pharmacies to compound BPC-157, against FDA staff advice17. That vote is non-binding, and as of 30 September 2026 FDA had not proposed a rule or changed BPC-157’s status28.

Is BPC-157 banned in sports?

Yes. WADA prohibits it at all times under class S0 (non-approved substances), and the 2027 List keeps it1112. Athletes in the US and Canada have received 4-year bans involving BPC-1573637.

BPC-157 vs TB-500: what’s the difference?

They are different molecules: BPC-157 is a 15-amino-acid peptide described as a fragment of a protein from human gastric juice, while FDA describes TB-500 as a 7-amino-acid fragment of thymosin beta-4 (amino acids 17 to 23) with an added acetyl group150. BPC-157 has a few small human studies, but FDA found no data from human studies of TB-500150. They are often sold together as the ‘Wolverine stack’, yet in a 2026 rat tendon study the combination did no better than either peptide alone1844.

Is BPC-157 safe, and what are its side effects?

No one knows. The published studies FDA found gave it to fewer than 100 people for 2 weeks or less, and FDA says it ‘lacks sufficient information to know whether the drug would cause harm when administered to humans’126. Reports to FDA include darkened skin and gums after a product that also held TB-500, redness and swelling where it was injected, and shortness of breath1. Other products taken at the same time, or missing details, limit what those reports show1. FDA also flags possible immune reactions, altered blood clotting in animal studies and impurities in products1.

Is BPC-157 bad for the heart?

No one knows: the published studies FDA found gave it to fewer than 100 people, for 2 weeks or less1. In a pilot in which 2 adults were given BPC-157 by vein, blood markers of heart function did not change5. In rats, a 28-day study reported no damage to the heart or other major organs, but FDA notes that the paper did not include the tissue data1.

Can BPC-157 cause liver damage?

No one knows: the published studies FDA found gave it to fewer than 100 people, for 2 weeks or less1. In a pilot in which 2 adults were given BPC-157 by vein, blood markers of liver function did not change5. In 28-day studies in rats and dogs, FDA reports raised liver-related blood markers, including the liver enzyme ALT, although the study authors called BPC-157 well tolerated140.

Does BPC-157 affect testosterone?

No study has measured it: a PubMed search on 7 October 2026 found 3 papers on BPC-157 and testosterone or the testes, and none measured testosterone after giving BPC-157, in people or animals51. FDA’s 2026 review of BPC-157 does not mention testosterone1.

What is still unknown

  • Will FDA propose a rule adding BPC-157 (free base or acetate) to the 503A bulks list after the 23 July 2026 advisory vote? None had been proposed as of 30 September 2026.
  • Is NCT07437547 (BPC-157 for hamstring strain, sponsor Hudson Biotech, listed as recruiting) a real trial? The same sponsor’s 2026 records include one that calls itself ‘fictional’ and one titled ‘(Mock Study)’, so it is not counted as evidence here.
  • Will the completed gummy study (NCT07752381, finished November 2025) or the 2015 oral tablet study (NCT02637284, status unknown) ever report results?
  • What happens to BPC-157 in people after injection under the skin, by mouth or in the nose? No human pharmacokinetic data exist for these routes.
  • Whether long-term use is safe, including for people with existing tumors, given BPC-157’s blood-vessel-growth activity in animals. We found no study of long-term safety.
  • Is BPC-157 a lawful dietary supplement ingredient in the US? FDA notes it is sold that way, but no FDA ruling on that question was found.
  • What were the 10 serious adverse event reports (8 in 2026) cited by Reuters? FDA’s adverse event dashboard was not queried directly.
  • Which salt or derivative is actually in products sold as BPC-157? FDA says several are sold under the same name.
  • Did New Zealand’s 2023 recommendation to make BPC-157 prescription-only take legal effect? What is its status in EU countries? Neither was verified.

Sources

  1. 1FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
  2. 2Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  3. 3Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Alternative Therapies in Health and Medicine, Jul 2021. pubmed.ncbi.nlm.nih.gov
  4. 4Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study Alternative Therapies in Health and Medicine, Oct 2024. pubmed.ncbi.nlm.nih.gov
  5. 5Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study Alternative Therapies in Health and Medicine, Sep 2025. pubmed.ncbi.nlm.nih.gov
  6. 6Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal, Nov 2025. pubmed.ncbi.nlm.nih.gov
  7. 7PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
  8. 8July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
  9. 9BPC-157 Safety Testing Results & Vendor Ratings Finnrick, 29 Sep 2026. finnrick.com
  10. 10Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
  11. 11World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  12. 12World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  13. 13A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC Journal of Physiology, Paris, 1993. pubmed.ncbi.nlm.nih.gov
  14. 14Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine, Mar 2017. pubmed.ncbi.nlm.nih.gov
  15. 15Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research, Nov 2003. pubmed.ncbi.nlm.nih.gov
  16. 16PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284) ClinicalTrials.gov, 22 Dec 2015. clinicaltrials.gov
  17. 17Bpc-157 (PubChem CID 9941957) PubChem, National Center for Biotechnology Information, accessed 1 Oct 2026. pubchem.ncbi.nlm.nih.gov
  18. 18Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Joint Diseases and Related Surgery, 23 Jul 2026. pubmed.ncbi.nlm.nih.gov
  19. 19A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery (NCT07752381) ClinicalTrials.gov, 7 Aug 2026. clinicaltrials.gov
  20. 20Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250) ClinicalTrials.gov, 3 Sep 2026. clinicaltrials.gov
  21. 21BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547) ClinicalTrials.gov, 27 Feb 2026. clinicaltrials.gov
  22. 22TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (NCT07487363) ClinicalTrials.gov, 23 Mar 2026. clinicaltrials.gov
  23. 23Warning letter to Warrior Labz SARMS (MARCS-CMS 655280) U.S. Food and Drug Administration, 12 Jun 2023. fda.gov
  24. 24Utah Licensed Osteopathic Physician Indicted for Allegedly Receiving Misbranded Drugs from China and Selling them to Patients U.S. Attorney’s Office, District of Utah, 1 Apr 2026. justice.gov
  25. 2521 CFR Part 1308, Schedules of Controlled Substances (eCFR, as of 25 September 2026) Electronic Code of Federal Regulations (eCFR), 25 Sep 2026. ecfr.gov
  26. 26Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
  27. 27As Hims prepares for peptides launch, Wall Street cautious on prospects this year Reuters (via Yahoo Finance), 12 Aug 2026. finance.yahoo.com
  28. 28Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
  29. 29GHK-Cu & BPC-157 powder: Unauthorized active pharmaceutical ingredients (RA-82047) Health Canada, 7 May 2026. recalls-rappels.canada.ca
  30. 30Doctors are using a regulatory gap to prescribe an unauthorized peptide CBC News, 24 Jul 2026. cbc.ca
  31. 31Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
  32. 32Medicines watchdog to investigate UK peptide clinics over health claims The Guardian, 4 Apr 2026. theguardian.com
  33. 33Minutes of the 70th meeting of the Medicines Classification Committee, 25 May 2023 Medsafe (New Zealand Medicines and Medical Devices Safety Authority), 25 May 2023. medsafe.govt.nz
  34. 34Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
  35. 35BPC-157: Experimental Peptide Creates Risk for Athletes U.S. Anti-Doping Agency, 10 Aug 2026. usada.org
  36. 36Triathlon Athlete Accepts Sanction for Anti-Doping Rule Violations U.S. Anti-Doping Agency, 17 Sep 2025. usada.org
  37. 37U SPORTS Volleyball Athlete Suspended for the Use of BPC-157 and TB-500 Sport Integrity Canada, 7 Apr 2025. sportintegrity.ca
  38. 38Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H Drug Testing and Analysis, Oct 2017. pubmed.ncbi.nlm.nih.gov
  39. 39Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs Frontiers in Pharmacology, 2022. pubmed.ncbi.nlm.nih.gov
  40. 40Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Regulatory Toxicology and Pharmacology, Jul 2020. pubmed.ncbi.nlm.nih.gov
  41. 41BPC-157: How It Works, Mechanism & Evidence (2026) The Peptide Catalog, 18 Apr 2026. thepeptidecatalog.com
  42. 42Methodology Finnrick, accessed 30 Sep 2026. finnrick.com
  43. 43BPC-157 10mg + TB-500 10mg (Wolverine Stack 20mg) Ascension Peptides (vendor), accessed 1 Oct 2026. ascensionpeptides.com (seller page, deliberately not linked)
  44. 44Use of experimental ‘Wolverine’ peptide backed by RFK Jr is on the rise, study finds The Independent (Reuters), 16 Sep 2026. independent.co.uk
  45. 45Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks (RA-81403) Health Canada, 24 Dec 2025. recalls-rappels.canada.ca
  46. 46We’d Rather Buy the Future Than Wait For It Finnrick, 10 Jun 2026. finnrick.com
  47. 47r/BPC_157 (official subreddit embed page; weekly visitors) Reddit, accessed 30 Sep 2026. embed.reddit.com
  48. 48Google Trends: rising related queries for ‘bpc 157’, United States, 12 months to 29 September 2026 Google Trends, accessed 30 Sep 2026. trends.google.com
  49. 49Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs Missouri Medicine, 2026. pubmed.ncbi.nlm.nih.gov
  50. 50FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: TB-500-related bulk drug substances U.S. Food and Drug Administration, 15 May 2026. fda.gov
  51. 51PubMed search: BPC-157 with testosterone, androgens, the testes, luteinizing hormone, sex hormones or gonads (3 results) National Library of Medicine (PubMed), accessed 7 Oct 2026. pubmed.ncbi.nlm.nih.gov
  52. 52Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024 (F2024L00589) Federal Register of Legislation, Australian Government, 28 May 2024. legislation.gov.au
  53. 53BPC-157 vs. Pentadeca Arginate (PDA): Unlocking the Healing Power of a Revolutionary Peptide American Wellness Pharmacy (vendor), 13 Jan 2026. americanwellnesspharmacy.com (seller page, deliberately not linked)
  54. 54Pentadeca Arginate: Next-Gen BPC-157 for Healing & Recovery All U Health (vendor), 31 Jul 2024. alluhealth.com (seller page, deliberately not linked)
  55. 55US 9,850,282 B2: Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy U.S. Patent and Trademark Office, 26 Dec 2017. image-ppubs.uspto.gov
  56. 56PubMed search: pentadeca arginate, pentadecapeptide arginate or BPC-157 arginate, or arginate or arginine salt with BPC 157, bepecin or pentadecapeptide (0 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.